ナノ医薬品の世界市場レポート 2024年

ナノ医薬品市場規模は、今後数年で急成長が見込まれます。2028年の年間平均成長率（CAGR）は17.0％で、1,838億9,000万米ドルに成長します。予測期間中に予想される成長は、慢性疾患の有病率の上昇、研究開発努力の増加、医療への投資拡大、個別化医療に対する需要の高まり、がんの発生率の増加など、いくつかの要因に起因しています。この期間に予想される主要動向には、ナノ技術と他の新興技術との統合、ナノ対応ドラッグデリバリーシステムの進歩、バイオテクノロジーとゲノミクスの進歩、AI、機械学習、計算モデリングの取り込み、継続的な技術革新などがあります。

慢性疾患の有病率の増加は、今後数年間のナノ医薬品市場の成長を促進すると予想されます。がん、糖尿病、心臓病、喘息などの慢性疾患は、一般的に継続的な医療措置と管理を必要とする長期的な疾患です。これらの疾患の有病率上昇の要因としては、不健康な食生活、運動不足、タバコの使用、過度のアルコール摂取、遺伝的素因、環境の影響などが挙げられます。ナノ医薬品は、標的ドラッグデリバリー、バイオアベイラビリティの向上、放出制御、副作用の軽減、先進的併用療法を提供することにより慢性疾患の治療に利用され、これらすべてが治療効果と患者の転帰を改善します。例えば、2022年4月、米国の非営利団体であるNational Association of Chronic Disease Directors（NACDD）は、米国成人の60％近くが少なくとも1つの慢性疾患に罹患しており、約40％が複数の慢性疾患（MCC）に罹患していると報告しました。この蔓延は、2030年までに米国経済に年間2兆米ドル、一人当たり8,600ドルの損失をもたらすと予想されています。このため、慢性疾患の増加がナノ医薬品市場の拡大に拍車をかけています。

ナノ医薬品市場の主要企業は、個人、企業、政府向けの通信サービスを強化するため、戦略的パートナーシップを採用するケースが増えています。戦略的パートナーシップとは、企業が互いの強みやリソースを活用し、相互利益と成功を達成することです。例えば、2024年4月、フィンランドを拠点とするナノ粒子医療企業であるNanoform Finland Plcは、日本を拠点とする開発専門商社である株式会社CBCと提携し、Nanoformの先進的ナノ医療工学技術のビジネス機会を模索しています。この協業は、最先端のナノ技術を活用し、世界中の患者のために医薬品を改善する取り組みにおける重要なマイルストーンとなります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の市場規模と成長

• 世界のナノ医薬品市場：促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のナノ医薬品市場の実績：規模と成長、2018～2023年
• 世界のナノ医薬品市場の予測：規模と成長、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のナノ医薬品市場：タイプ別、実績と予測、2018～2023年、2023～2028年、2033年
• リポソーム
• 高分子ミセル
• 固体脂質ナノ粒子
• マイクロエマルジョン
• ナノエマルジョン
• その他
• 世界のナノ医薬品市場：投与経路別、実績と予測、2018～2023年、2023～2028年、2033年
• 経口
• 注射
• 局所
• 経肺
• その他
• 世界のナノ医薬品市場：用途別、実績と予測、2018～2023年、2023～2028年、2033年
• 腫瘍学
• 神経学
• 抗炎症
• 抗感染
• 心臓血管
• その他
• 世界のナノ医薬品市場：エンドユーザー別、実績と予測、2018～2023年、2023～2028年、2033年
• 病院とクリニック
• 専門薬局
• 研究機関
• その他

第7章 地域別・国別分析

• 世界のナノ医薬品市場：地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界のナノ医薬品市場：国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ナノ医薬品市場：競合情勢
• ナノ医薬品市場：企業プロファイル
  • Selecta Biosciences Inc.
  • Pfizer Inc.
  • Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • AbbVie Inc.

第31章 その他の大手企業と革新的企業

• Bayer AG
• Sanofi S.A.
• Bristol Myers Squibb Company
• AstraZeneca plc
• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Novovax Inc.
• OSI Pharmaceuticals Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在的な分析

第36章 付録

Nanopharmaceuticals are a category of pharmaceutical drugs that leverage nanotechnology to enhance the delivery, targeting, and effectiveness of therapeutic agents. These drugs are formulated at the nanoscale, typically ranging from 1 to 100 nanometers, and are designed to improve drug solubility, stability, bioavailability, and targeted delivery to specific cells or tissues. Nanopharmaceuticals represent an advanced approach in medicine, offering the potential for more precise, effective, and safer treatments across various diseases.

The primary types of nanopharmaceuticals include liposomes, polymeric micelles, solid lipid nanoparticles, microemulsions, nanoemulsions, and others. Liposomes are small, spherical vesicles composed of phospholipids that can encapsulate drugs, enhancing their delivery to targeted cells or tissues. They help protect the drug from degradation and improve its absorption. Nanopharmaceuticals can be administered through various routes, including oral, injectable, topical, pulmonary, and others. Their applications span multiple therapeutic areas such as oncology, neurology, anti-inflammatory, anti-infective, cardiovascular, and more. These drugs are utilized by several end-users, including hospitals and clinics, specialty pharmacies, research institutions, and others.

The nanopharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides nanopharmaceuticals market statistics, including nanopharmaceuticals industry global market size, regional shares, competitors with a nanopharmaceuticals market share, detailed nanopharmaceuticals market segments, market trends, and opportunities, and any further data you may need to thrive in the nanopharmaceuticals industry. This nanopharmaceuticals research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nanopharmaceuticals market size has grown rapidly in recent years. It will grow from $80.97 billion in 2023 to $95.21 billion in 2024 at a compound annual growth rate (CAGR) of 17.6%. The historical growth can be attributed to several factors, including the demand for more effective treatments, growing awareness of nanopharmaceuticals, an increasing demand for targeted therapies, rising incidences of neurodegenerative diseases, and the aging population.

The nanopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $183.89 billion in 2028 at a compound annual growth rate (CAGR) of 17.0%. The anticipated growth during the forecast period can be attributed to several factors, including the rising prevalence of chronic diseases, increased research and development efforts, growing investments in healthcare, heightened demand for personalized medicine, and the increasing incidence of cancers. Key trends expected during this period include the integration of nanotechnology with other emerging technologies, advancements in nano-enabled drug delivery systems, progress in biotechnology and genomics, the incorporation of AI, machine learning, and computational modeling, and continued technological innovation.

The increasing prevalence of chronic diseases is expected to drive the growth of the nanopharmaceuticals market in the coming years. Chronic diseases, such as cancer, diabetes, heart disease, and asthma, are long-term conditions that typically require ongoing medical attention and management. Factors contributing to the rising prevalence of these diseases include unhealthy diets, lack of physical activity, tobacco use, excessive alcohol consumption, genetic predisposition, and environmental influences. Nanopharmaceuticals are utilized in treating chronic diseases by offering targeted drug delivery, enhanced bioavailability, controlled release, reduced side effects, and advanced combination therapies, all of which improve treatment efficacy and patient outcomes. For example, in April 2022, the National Association of Chronic Disease Directors (NACDD), a US-based non-profit organization, reported that nearly 60% of American adults have at least one chronic disease, and around 40% have multiple chronic conditions (MCC). This prevalence is expected to cost the US economy $2 trillion annually, or $8,600 per person, by 2030. Therefore, the growing incidence of chronic diseases is fueling the expansion of the nanopharmaceuticals market.

Major companies in the nanopharmaceuticals market are increasingly adopting strategic partnerships to enhance communication services for individuals, businesses, and governments. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits and success. For example, in April 2024, Nanoform Finland Plc, a Finland-based nanoparticle medicine company, joined forces with CBC Co. Ltd., a Japan-based development-focused trading company, to explore opportunities for Nanoform's advanced nanomedicine engineering technologies. This collaboration represents a significant milestone in their efforts to utilize cutting-edge nanotechnology to improve medicines for patients globally.

In February 2022, Merck KGaA, a Germany-based company specializing in healthcare, life sciences, and performance materials, acquired Exelead Inc. for $780 million. This acquisition aims to strengthen Merck's capabilities in advanced drug delivery, particularly by integrating Exelead's expertise in lipid nanoparticle technology, which is essential for developing and producing innovative therapies, including mRNA-based treatments. Exelead Inc. is a US-based company that manufactures complex injectable formulations, including lipid nanoparticle (LNP) technology.

Major companies operating in the nanopharmaceuticals market are Selecta Biosciences Inc., Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Abvie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Stryker Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Novovax Inc., OSI Pharmaceuticals Inc., Par Pharmaceutial Inc., Samyang Biopharm Corporation

North America was the largest region in the global nanopharmaceuticals market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nanopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nanopharmaceuticals market consists of sales of dendritic nanoparticles, quantum dots, micellar nanoparticles, and gene delivery systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nanopharmaceuticals Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nanopharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nanopharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nanopharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Liposomes; Polymeric Micelles; Solid Lipid Nanoparticles; Microemulsion; Nanoemulsion; Other Product Types
• 2) By Route Of Administration: Oral; Injectable; Topical; Pulmonary; Other Routes Of Administration
• 3) By Application: Oncology; Neurology; Anti-inflammatory; Anti-infective; Cardiovascular; Other Applications
• 4) By End-User: Hospitals And Clinics; Specialty Pharmacies; Research Institutions; Other End Users
• Companies Mentioned: Selecta Biosciences Inc.; Pfizer Inc.; Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nanopharmaceuticals Market Characteristics

3. Nanopharmaceuticals Market Trends And Strategies

4. Nanopharmaceuticals Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Nanopharmaceuticals Market Size and Growth

• 5.1. Global Nanopharmaceuticals Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Nanopharmaceuticals Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Nanopharmaceuticals Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Nanopharmaceuticals Market Segmentation

• 6.1. Global Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Liposomes
• Polymeric Micelles
• Solid Lipid Nanoparticles
• Microemulsion
• Nanoemulsion
• Other Product Types
• 6.2. Global Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Injectable
• Topical
• Pulmonary
• Other Routes Of Administration
• 6.3. Global Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oncology
• Neurology
• Anti-inflammatory
• Anti-infective
• Cardiovascular
• Other Applications
• 6.4. Global Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals And Clinics
• Specialty Pharmacies
• Research Institutions
• Other End Users

7. Nanopharmaceuticals Market Regional And Country Analysis

• 7.1. Global Nanopharmaceuticals Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Nanopharmaceuticals Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Nanopharmaceuticals Market

• 8.1. Asia-Pacific Nanopharmaceuticals Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Nanopharmaceuticals Market

• 9.1. China Nanopharmaceuticals Market Overview
• 9.2. China Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Nanopharmaceuticals Market

• 10.1. India Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Nanopharmaceuticals Market

• 11.1. Japan Nanopharmaceuticals Market Overview
• 11.2. Japan Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Nanopharmaceuticals Market

• 12.1. Australia Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Nanopharmaceuticals Market

• 13.1. Indonesia Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Nanopharmaceuticals Market

• 14.1. South Korea Nanopharmaceuticals Market Overview
• 14.2. South Korea Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Nanopharmaceuticals Market

• 15.1. Western Europe Nanopharmaceuticals Market Overview
• 15.2. Western Europe Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Nanopharmaceuticals Market

• 16.1. UK Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Nanopharmaceuticals Market

• 17.1. Germany Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Nanopharmaceuticals Market

• 18.1. France Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Nanopharmaceuticals Market

• 19.1. Italy Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Nanopharmaceuticals Market

• 20.1. Spain Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Nanopharmaceuticals Market

• 21.1. Eastern Europe Nanopharmaceuticals Market Overview
• 21.2. Eastern Europe Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Nanopharmaceuticals Market

• 22.1. Russia Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Nanopharmaceuticals Market

• 23.1. North America Nanopharmaceuticals Market Overview
• 23.2. North America Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Nanopharmaceuticals Market

• 24.1. USA Nanopharmaceuticals Market Overview
• 24.2. USA Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Nanopharmaceuticals Market

• 25.1. Canada Nanopharmaceuticals Market Overview
• 25.2. Canada Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Nanopharmaceuticals Market

• 26.1. South America Nanopharmaceuticals Market Overview
• 26.2. South America Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Nanopharmaceuticals Market

• 27.1. Brazil Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Nanopharmaceuticals Market

• 28.1. Middle East Nanopharmaceuticals Market Overview
• 28.2. Middle East Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Nanopharmaceuticals Market

• 29.1. Africa Nanopharmaceuticals Market Overview
• 29.2. Africa Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Nanopharmaceuticals Market Competitive Landscape And Company Profiles

• 30.1. Nanopharmaceuticals Market Competitive Landscape
• 30.2. Nanopharmaceuticals Market Company Profiles
  • 30.2.1. Selecta Biosciences Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Hoffmann-La Roche Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Merck & Co. Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AbbVie Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Nanopharmaceuticals Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi S.A.
• 31.3. Bristol Myers Squibb Company
• 31.4. AstraZeneca plc
• 31.5. Abbott Laboratories
• 31.6. Novartis AG
• 31.7. GlaxoSmithKline plc
• 31.8. Eli Lilly and Company
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Amgen Inc.
• 31.11. Stryker Corporation
• 31.12. Teva Pharmaceutical Industries Ltd.
• 31.13. Astellas Pharma Inc.
• 31.14. Novovax Inc.
• 31.15. OSI Pharmaceuticals Inc.

32. Global Nanopharmaceuticals Market Competitive Benchmarking

33. Global Nanopharmaceuticals Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Nanopharmaceuticals Market

35. Nanopharmaceuticals Market Future Outlook and Potential Analysis

• 35.1 Nanopharmaceuticals Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Nanopharmaceuticals Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Nanopharmaceuticals Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer